I n addition to their origins as treatment for type 2 diabetes, GLP-1 receptor agonists like Ozempic and Wegovy are often ...

The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

Research shows that glucagon-like peptide-1 receptor agonists (or GLP-1s – think Ozempic or similar medications) are changing ...

WSHU sits down with CT Mirror’s Katy Golvala to discuss her story about the debate over Medicaid coverage of weight loss ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their ...

GLP-1 weight loss drugs cost CT’s Medicaid program $85 million in FY 2024, 35% of annual Medicaid pharmaceutical budget ...